NCT07041788

Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC

Not yet recruiting Phase 2 Last updated 27 June 2025

What this trial tests

Phase 2 trial testing Iparomlimab and Tuvonralimab Injection in Cancer in 25 participants. Not yet recruiting.

Timeline

10 July 2025

Primary endpoint
9 July 2028

9 July 2030

Quick facts

Lead sponsor	Second Affiliated Hospital of Nanchang University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	10 July 2025
Primary completion	9 July 2028
Estimated completion	9 July 2030
Sites	1 location across China

Drugs / interventions tested

• Iparomlimab and Tuvonralimab Injection — full drug profile →

Conditions studied

• Cancer — all drugs for Cancer →

Sponsor

Second Affiliated Hospital of Nanchang University

Who can join

Adults 18 to 75, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study Objectives

1. Primary Objective:

The core aim of this study is to investigate whether the sequential approach of Spatially Fractionated Radiotherapy followed by 3 cycles of induction chemotherapy combined with Iparomlimab and Tuvonralimab, definitive chemoradiotherapy, and maintenance therapy with the Iparomlimab and Tuvonralimab can improve the 2-year event-free survival (EFS) rate in patients with locoregionally advanced bulky head and neck squamous cell carcinoma (HNSCC).
2. Secondary Objectives:s

To analyze the impact of this integrated treatment regimen on key efficacy endpoints, including:

Objective response rate (ORR), Duration of response (DoR), Distant metastasis-free survival (DMFS), Local region recurrence-free survival (LRRFS), Overall survival (OS)。 2. Study Endpoints

(1) Primary Endpoint and Definition: 2-Year Event-Free Survival (EFS) Rate (2) Secondary Endpoints and Definitions:

1. 2-Year Overall Survival (OS) Rate
2. 2-Year Distant Metastasis-Free Survival (DMFS) Rate.
3. 2-Year Local Region Recurrence-Free Survival (LRRFS) Rate.
4. Objective Response Rate (ORR).
5. Duration of Response (DoR).
6. Quality of Life (QoL):

Assessed across multiple domains:

Physical Function: Measured via tools like the 6-minute walk test or ADL (Activities of Daily Living) scale.

Psychological Status: Evaluated using instruments such as HAMD (Hamilton Anxiety and Depression Scale) or MMSE (Mini-Mental State Examination).

Social Function: Assessed via social engagement questionnaires (e.g., HAQ-DI \[Health Assessment Questionnaire-Disability Index\]).

Spiritual Well-being: Evaluated using tools like PIL (Purpose in Life test). Clinically meaningful improvements in these domains before and after treatment define successful QoL endpoints (e.g., positive changes in physical, psychological, social, and spiritual health in cardiac patients).
7. Safety:

The nature and severity of adverse reactions associated with the treatment.
8. Tolerability:

The degree to which patients can endure treatment-related side effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.